| Original language | English |
|---|---|
| Pages (from-to) | 339-357 |
| Number of pages | 19 |
| Journal | Annals of Oncology |
| Volume | 34 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1 Apr 2023 |
Keywords
- ESCAT
- ESMO Clinical Practice Guideline (CPG)
- ESMO-MCBS
- oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC)
- targeted therapy
- treatment
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Annals of Oncology, Vol. 34, No. 4, 01.04.2023, p. 339-357.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Oncogene-addicted metastatic non-small-cell lung cancer
T2 - ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
AU - ESMO Guidelines Committee
AU - Hendriks, L. E.
AU - Kerr, K. M.
AU - Menis, J.
AU - Mok, T. S.
AU - Nestle, U.
AU - Passaro, A.
AU - Peters, S.
AU - Planchard, D.
AU - Smit, E. F.
AU - Solomon, B. J.
AU - Veronesi, G.
AU - Reck, M.
N1 - Funding Information: UN reports fees paid to her institution as an invited speaker from MSD; fees paid to her institution for advisory board membership and a writing engagement from AstraZeneca; institutional funding as a coordinating PI for Bayer; non-remunerated roles as a PI for clinical trials funded by Deutsche Krebshilfe and as a member of the board of directors and vice-chair of ‘Strahlenschutzkommission’ from the German Commission on Radiological Protection. Funding Information: Manuscript editing support was provided by Richard Lutz, Fraser Simpson, Claire Bramley, Catherine Evans, Jennifer Lamarre and Guy Atchison (ESMO Guidelines staff); this support was funded by ESMO . Nathan Cherny, Chair of the ESMO-MCBS Working Group, Urania Dafni and Giota Zygoura of Frontier Science Foundation Hellas provided review and validation of the ESMO-MCBS scores. Nicola Latino ( ESMO Scientific Affairs staff) provided coordination and support of the ESMO-MCBS scores and Angela Corstorphine of KMC provided medical writing and editing support in the preparation of the ESMO-MCBS table; this support was funded by ESMO . Dr Jordi Remón Masip (on behalf of the ESMO Translational Research and Precision Medicine Working Group) and Dr Svetlana Jezdic ( ESMO Medical Affairs Advisor) provided validation support for ESCAT scores. Matt Hellmann provided initial writing support during the conception of this guideline.
PY - 2023/4/1
Y1 - 2023/4/1
KW - ESCAT
KW - ESMO Clinical Practice Guideline (CPG)
KW - ESMO-MCBS
KW - oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC)
KW - targeted therapy
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85151569857&partnerID=8YFLogxK
U2 - 10.1016/j.annonc.2022.12.009
DO - 10.1016/j.annonc.2022.12.009
M3 - Article
C2 - 36872130
AN - SCOPUS:85151569857
SN - 0923-7534
VL - 34
SP - 339
EP - 357
JO - Annals of Oncology
JF - Annals of Oncology
IS - 4
ER -